Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives-Reference-Cited by-同舟云学术

Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives

Published:2022-12 Issue:S2 Volume:62 Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Liu Jing¹,Barrett Jeffrey S.²,Leonardi Efthimia T.³,Lee Lucy³,Roychoudhury Satrajit¹,Chen Yong¹,Trifillis Panayiota³

Affiliation:

1. Pfizer, Inc. Groton Connecticut USA

2. Critical Path Institute Rare Disease Cures Accelerator Data Analytics Platform Tucson Arizona USA

3. PTC Therapeutics, Inc. South Plainfield New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2134

Reference116 articles.

1. US Food and Drug Administration.Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry.2019. Accessed March 4 2022.https://www.fda.gov/media/122425/download

2. European Medicines Agency.Procedural advice for orphan medicinal product designation: Guidance for sponsors.2021. Accessed March 4 2022.https://www.ema.europa.eu/en/documents/regulatory‐procedural‐guideline/procedural‐advice‐orphan‐medicinal‐product‐designation‐guidance‐sponsors_en.pdf

3. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database

4. US Food and Drug Administration.Importance of natural history studies in rare diseases.2019. Accessed March 4 2022.https://events‐support.com/Documents/Pariser.pdf

5. Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on the current status of CRISPR based clinical trials for rare diseases;International Journal of Biological Macromolecules;2024-10

2. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial;npj Digital Medicine;2024-08-27

3. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks;Therapeutic Innovation & Regulatory Science;2024-07-25

4. Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review;Diagnostics;2024-07-19

5. New Horizons of Model Informed Drug Development in Rare Diseases Drug Development;Clinical Pharmacology & Therapeutics;2024-07-11